Google
 

Archive for the ‘Liver Disease / Hepatitis’ Category

Shorter Legs Linked To Liver Disease

Tuesday, December 18th, 2007

Short legs are linked to an increased risk of liver disease, suggests a study in the Journal of Epidemiology and Community Health. The research contributes to a growing body of evidence on the link between leg length and health. The findings are based on almost 4300 women between the ages ...

European Medicines Agency Recommends Withdrawal Of The Marketing Authorisations For Lumiracoxib-Containing Medicines

Friday, December 14th, 2007

The European Medicines Agency (EMEA) has recommended the withdrawal of the marketing authorisations for all lumiracoxib-containing medicines, because of the risk of serious side effects affecting the liver. Lumiracoxib is a non-steroidal anti-inflammatory drug (NSAID) that belongs to the group 'COX-2 inhibitors'. It is used for symptomatic relief in the ...

XTL Biopharmaceuticals Presents Data Regarding Its Hepatitis C Virus Small Molecule Program At Hep Dart 2007

Tuesday, December 11th, 2007

XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB, TASE: XTL) announced that it will make two scientific presentations related to its pre-clinical Hepatitis C virus (HCV) small molecule program at HEP DART 2007, an international scientific conference on viral hepatitis being held this week in Lahaina, Hawaii. A poster presentation entitled ...

In Adolescent Males New Upper Limit Defined For Normal ALT

Tuesday, December 4th, 2007

A new cohort study of adolescent offenders in Australia has identified an upper limit for ALT that is more sensitive for the diagnosis of liver disease. The findings could facilitate targeted interventions for the youths in this group, who are at high risk for HCV infection and obesity-related liver disease. ...

Treating Patients With Psychiatric Disorders For Hepatitis C

Tuesday, December 4th, 2007

People with severe mental illnesses are far more likely to be infected with Hepatitis C virus compared to the general population, however, they often do not get treatment for their liver disease because current antiviral therapies have known psychiatric side effects."Against this epidemiological background, the article by Schaefer and colleagues, ...

GNI Announces IND Approval In China For Novel Liver Disease Drug F351

Friday, November 23rd, 2007

GNI Ltd (TOKYO:2160), a leading biopharmaceutical company in Japan and China, is pleased to announce that the State Food and Drug Administration of China has approved its Investigational New Drug application (IND) for the clinical development of one of its lead drug candidates, F351, for the treatment of liver fibrosis/cirrhosis. ...

The American Liver Foundation Encourages Heightened Awareness Of Hepatitis B And C In Light Of Recent Events In The News

Friday, November 23rd, 2007

The following release and statements are attributed to The American Liver Foundation: The American Liver Foundation, a nonprofit organization dedicated to raising awareness and improving the quality of life for the 30 million Americans with liver disease, issued a statement today expressing its concern over the recent reports that ...

Health Canada Licenses QIAGEN’s New Molecular Test For Hepatitis B

Thursday, November 22nd, 2007

QIAGEN announced that its newly released hepatitis B virus (HBV) assay kit is in compliance with Health Canada's medical device requirements. The artus HBV LC PCR Kit, which monitors the viral load of HBV infected patients, is now available to doctors in Canada to help them determine the success of ...

Prexige (Lumiracoxib) Licence Has Been Suspended, UK

Thursday, November 22nd, 2007

The Medicines and Healthcare products Regulatory Agency (MHRA) is informing healthcare professionals about the suspension of the licence for Prexige (lumiracoxib) due to the safety concerns about possible liver damage for patients. In August 2007, following analysis of data available at that time, the MHRA introduced new prescribing restrictions (contraindications) ...

MIT: ‘Micro’ Livers Could Aid Drug Screening

Monday, November 19th, 2007

MIT researchers have devised a novel way to create tiny colonies of living human liver cells that model the full-sized organ. The work could allow better screening of new drugs that are potentially harmful to the liver and reduce the costs associated with their development. Liver ...

St. Vincent Medical Center Opens Innovative Clinic To Fight Hepatitis

Thursday, November 15th, 2007

In a unique effort to fight hepatitis in the greater Los Angeles area, St. Vincent Medical Center has opened the Asian Pacific Liver Center (APLC), the only clinic in Southern California dedicated to the prevention, detection and treatment of hepatitis, with special emphasis on the high rate of disease in ...

Gilead Announces 48-Week Data From Two Pivotal Phase III StudiesEvaluating Viread(R) For The Treatment Of Chronic Hepatitis B

Tuesday, November 6th, 2007

Gilead Sciences, Inc. (Nasdaq: GILD) announced the presentation of detailed 48-week data from two phase III pivotal clinical trials, Studies 102 and 103, which evaluate the safety and efficacy of once-daily Viread® (tenofovir disoproxil fumarate) among adult patients with chronic hepatitis B virus (HBV) infection. The data are being ...

Plasma Serotonin Levels Can Correlate With Degree Of Liver Insufficiency

Tuesday, November 6th, 2007

Liver cirrhosis is a worldwide disease with an incidence of 5 to 10% and represents a major health problem everywhere. Prognosis depends on the degree of liver damage and etiology of cirrhosis. Treatment is complex and often very expensive. Due to this, the attempts of researchers are focused on finding ...

Survival In Hepatitis C Virus Patients Prolonged By 24-Week Course Of Interferon-Alpha Therapy

Tuesday, November 6th, 2007

Patients with the hepatitis C virus (HCV) have a risk of frequent recurrence and deterioration of liver function, even after curative treatment for the primary hepatocellular carcinoma (HCC). This unfavorable prognosis is associated with a sustained HCV infection. Thus, both the prevention of HCC recurrence and the preservation of liver ...

Nationwide Decrease In The Need For Liver Transplant

Tuesday, November 6th, 2007

A new Mayo Clinic study found a nationwide decrease in the need for liver transplant in patients with hepatitis B, which coincides with the increasingly widespread use of oral antiviral medications to slow disease progression. The study will be presented this week at the annual meeting of the American Association ...